RE: RE: NCI MeetingWhats key?
Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics Program (NExT).
Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio
So
GAP107-B8 is already a part of the NExT portfolio.
https://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=GAP&t=LIST&m=27609650&l=0&pd=0&r=0
The NExT program has grown out of the reality that the number of new anticancer agents reaching human clinical trials has been modest. Even when compounds do proceed to clinical testing, they often fail because of unexpected toxicities or are not effective. NExT not only
allows phase 0 trials to be conducted in humans, it brings together the teams of scientists necessary to develop and perform assays that can measure the biological effects of potential new anticancer agents. The assays provide a tool for the systematic removal of investigational agents from NCI's drug development pipeline that do not show expected biological effects and inform and
expedite decisions about further clinical development.
https://dctd.cancer.gov/About/major_initiatives_NExt.htm